Ann: 2021 Full Year Investor Presentation, page-13

Buying in as a contrarian play is taking on the risks that Nextstellis is a dud, that dermatology and Contract Services are also duds and that generic margins continue to be squeezed and that Nuvaring never gets approved or too late to have a meaningful impact on sales.

That is a lot of risk.

I am making the same assessment as to whether to sell and take a 60% loss from my initial investment back in Nov'16. The opportunity loss alone is huge.

I believe Nexstellis will be a good investment.
I believe that MYX has developed a solid dermatology business.
I believe that Contract Services is a very good business and is a sleeper.
I could not care less about Nuvaring, it's not there now so why bother being 4th to market.
Ah generics. What a crock. I wish they would sell it.

So my dilemma is: Can Nexstellis+Dermatology+Contract Services overcome the demise in generics with Scott Richards at the helm?

For me the jury is out, but the clock is now ticking very loudly.